NEW YORK (GenomeWeb) – Enzo Biochem today reported flat year-over-year revenues for its fiscal third quarter. 

For the three months ended April 30, the firm recorded total revenues of $24 million, the same as a year ago. Enzo Clinical Labs' revenues were up 8 percent to $15.7 million from $14.5 million, but Life Sciences revenues, which comprise Enzo's product revenues, slid 9 percent to $7.9 million from $8.7 million due to the effects of currency exchange and the timing of customer reordering patterns, Enzo said. Royalty and license fee income dropped to $423,000 from $729,000. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.